Advertisement

Community Oncology Alliance publishes IV Fluid Shortage Survey

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE COMMUNITY ONCOLOGY ALLIANCE released the results of its IV Fluid Shortage Survey. Sixty-six practices from across the country were surveyed. The results showed that:

  • 85 percent of the practices surveyed have received warnings from multiple manufacturers and/or have been impacted by the shortage of IV fluids
  • 44 percent of the practices surveyed have adjusted how and when fluids are used, are pursuing additional distributors to meet their patients’ needs, and/or are attempting to create excess inventory against further shortages
  • Less than 15% of the practices surveyed have made no changes in light of the current or future shortages

The complete survey results, including comments from participants, are available on the COA website.

Advertisement
Advertisement

YOU MAY BE INTERESTED IN

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.
Advertisement
Advertisement